PS
DSGN icon

Principal Securities’s Design Therapeutics DSGN Stock Holding History

Principal Securities’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74
Closed -$457 – 3742
2025
Q1 		$457 Hold
74
– – ﹤0.01% 3372
2024
Q4 		$457 Hold
74
– – ﹤0.01% 3367
2024
Q3 		$398 Hold
74
– – ﹤0.01% 3307
2024
Q2 		$248 Buy
+74
New +$288 ﹤0.01% 3286

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Principal Securities's DSGN Position: Q2 2025 in Review

Principal Securities sold out of Design Therapeutics (DSGN) in Q2 2025, closing a stake of 74 shares — an estimated $457 sold.

Principal Securities first reported a position in DSGN in Q2 2024 and held it in 4 quarters. The position peaked at $457 in Q1 2025. 92 funds tracked by Wall St. Rank hold DSGN as of Q2 2025.

  • Principal Securities reported no remaining Design Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 74 Design Therapeutics shares in Q2 2025, an estimated $457.
  • Principal Securities first reported a position in Design Therapeutics in Q2 2024 and held it in 4 quarters.
  • Principal Securities's Design Therapeutics position peaked at $457 in Q1 2025.
  • 92 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.